Overexpression of the oncoprotein HER2 in breast carcinoma in a population of young women in western Algeria

Abstract

Introduction: In west of Algeria, the incidence of breast cancer increased by 19.5% from 1996 to 2004. With a standardized incidence of 36.9 / 100,000. Invasive ductal carcinoma is the most histologic type as found.The HER family (Humen Epithelial Receptor), consisting of four members, HER2, is characteristic of receptor tyrosine kinase plays a fundamental role in the development and / or the growth of many human cancers.Evaluation of overexpression and quantification of the HER2 protein in situ can target HER2 + patients may benefit from specific therapy (Herceptin - Trastuzumab-).Immunohistochemical technique allows the identification and location of the overexpression of HER2 protein with the visualization of the target molecule on fixed tissue embedded in paraffin, taking into account that tumor cells invasive HER2 +.Patients and methods: Our study, include 134 young women with invasive breast cancer, is realized from June 2007 to January 2011 at Oran CHU, anatomopathology laboratory and in developpement biology and differentiation laboratory. The aim of this work is the determination of clinicopathologic and biologic carcteristics of invasive brest carcinoma HER2+ in young women of west Algeria.Results: The status of the HER2 oncoprotein highlighted by the antibody DAKO: with HER2 (score 0 and 1) 51.67%, HER2 (score 2 +) 6.05 %, HER2 + (3 + score) 43.28%, age of these patients is between 20 and 50 years (mean age 40 ± 05.03 years), the right breast is the site most affected (79%), the upper outer quadrant is the location found most (57%). Postsurgical size pT2 (69%), poorly differentiated tumors and undifferentiated G (77%), the SBR grading II & SBR III (80%), the invasion of axillary nodes N + (72%). The hormone receptor status identified by antibodies DAKO: RE-(77%), PR- (66%) & ER-PR- (62%).Conclusion: HER2 overexpression has three interests: pejorative prognostic value, predictive value and requirements for the treatment of invasive breast cancers.Only patients whose tumors over-express HER2 (score 3 + score 2 + and confirmed by FISH) may benefit from targeted therapy with trastuzumab. Introduction: In west of Algeria, the incidence of breast cancer increased by 19.5% from 1996 to 2004. With a standardized incidence of 36.9 / 100,000. Invasive ductal carcinoma is the most histologic type as found. The HER family (Humen Epithelial Receptor), consisting of four members, HER2, is characteristic of receptor tyrosine kinase plays a fundamental role in the development and / or the growth of many human cancers. Evaluation of overexpression and quantification of the HER2 protein in situ can target HER2 + patients may benefit from specific therapy (Herceptin - Trastuzumab-). Immunohistochemical technique allows the identification and location of the overexpression of HER2 protein with the visualization of the target molecule on fixed tissue embedded in paraffin, taking into account that tumor cells invasive HER2 +. Patients and methods: Our study, include 134 young women with invasive breast cancer, is realized from June 2007 to January 2011 at Oran CHU, anatomopathology laboratory and in developpement biology and differentiation laboratory. The aim of this work is the determination of clinicopathologic and biologic carcteristics of invasive brest carcinoma HER2+ in young women of west Algeria. Results: The status of the HER2 oncoprotein highlighted by the antibody DAKO: with HER2 (score 0 and 1) 51.67%, HER2 (score 2 +) 6.05 %, HER2 + (3 + score) 43.28%, age of these patients is between 20 and 50 years (mean age 40 ± 05.03 years), the right breast is the site most affected (79%), the upper outer quadrant is the location found most (57%). Postsurgical size pT2 (69%), poorly differentiated tumors and undifferentiated G (77%), the SBR grading II & SBR III (80%), the invasion of axillary nodes N + (72%). The hormone receptor status identified by antibodies DAKO: RE-(77%), PR- (66%) & ER-PR- (62%). Conclusion: HER2 overexpression has three interests: pejorative prognostic value, predictive value and requirements for the treatment of invasive breast cancers. Only patients whose tumors over-express HER2 (score 3 + score 2 + and confirmed by FISH) may benefit from targeted therapy with trastuzumab.